Endoxifen downregulates AKT phosphorylation through protein kinase C beta 1 inhibition in ERα+ breast cancer

RT @mpgoetz: Endoxifen is known to be a more potent inhibitor of ER alpha compared to tamoxifen.  Based on an unbiased proteomic screen, we…

Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha binding at nanomolar concentrations. These findings show that PKCβ1/ENDX interactions suppress AKT signaling and induce apoptosis in breast cancer. ht

Endoxifen, a secondary tamoxifen metabolite, is a potent antiestrogen exhibiting estrogen receptor alpha binding at nanomolar concentrations. These findings show that PKCβ1/ENDX interactions suppress AKT signaling and induce apoptosis in breast cancer. ht

$ATOS Either the market is ignoring one of the greatest gold mines to exist right now, or Quay has decided to tarnish his reputation and lie to the public for a pump. My money is on the former. We have gold people. #Biotech #breastcancer #HappyNewYear2